Mr. Speaker, the most concrete thing we are doing is working with our provincial and territorial colleagues on the development of new national guidelines which the provinces and territories can then enforce.
Lost her last election, in 2006, with 39% of the vote.
Health May 2nd, 2002
Mr. Speaker, the most concrete thing we are doing is working with our provincial and territorial colleagues on the development of new national guidelines which the provinces and territories can then enforce.
Question No. 126— April 30th, 2002
Since the beginning of the Canadian adverse drug reaction monitoring program, CADRMP, in 1965, 155,000 domestic suspected adverse reaction reports have been received and entered into one of several databases used over this period of time.
There are more than 20,000 drug products approved and marketed in Canada. Product and company information, including the date of market notification, for these drugs is contained in Health Canada’s drug product database. Some of the information in the database is available through the Health Canada website.
The date of receipt of adverse reaction reports is included in the adverse reaction database maintained by Health Canada. Due to the volume of suspected adverse reaction and medication incident reports, the database does not link to actions in response to each report of suspected reaction. Moreover, actions in response to suspected adverse reaction reports usually follow detection and confirmation of a new signal or trend concerning a safety issue associated with a marketed drug or other health product as discovered by creating a series of case reports. In other words, a market intervention or action is taken once a sufficient level of scientific evidence from case reports of suspected adverse reactions or medication incidents has been received.
Adverse reaction reports to marketed health products are considered to be suspicious, as a definite causal association often cannot be determined. In some cases the reported clinical data may be incomplete, or the given reaction may be due to the underlying disease or to another coincidental factor. Signals may be identified through the systematic review of adverse reaction reports and any other additional information on product safety.
Potential signals need expert evaluation before more actions are undertaken. Actions must be based on scientific analysis of case series and this implies an evaluation of the signal and the appropriate benefit-risk review of the information available. Actions may vary depending on the nature, the seriousness and the frequency of the reaction, as well as on the intended use of the health product, the benefit obtained from its use versus the risks and the availability of alternative therapies.
Information concerning regulatory actions taken in response to submitted suspected adverse reactions and medication incidents is available on the Health Canada website. Health Canada posts advisories, Dear Health Care Professional letters, summary fact sheets and “It’s Your Health” issues on the Health Canada website. Health care professionals and consumers can subscribe to the Health_Prod_ Info electronic mailing list to receive timely safety information and notification of regulatory actions.
Since 1991, the Canadian adverse reaction newsletter has also summarized case reports of suspected adverse reactions and medication incidents and provides additional information regarding regulatory actions. For example, in the period from June 2001 to February 2002, 32 advisories for health professionals and consumers concerning drugs and health products have been posted on the Health Canada website.
Health April 26th, 2002
Mr. Speaker, let me reiterate that under a court accepted settlement agreement there is an administrator in place. He has received in total to date approximately 5,500 claims. Over 1,700 of those claims have been verified by an independent administrator and they are receiving compensation.
It is simply not correct for the hon. member to suggest that victims of hepatitis C are not receiving compensation under this settlement agreement.
Health April 26th, 2002
Mr. Speaker, indeed this government has a heart. That is why we contributed hundreds of millions of dollars to a court accepted settlement agreement for those victims of hepatitis C between 1986 and 1990.
Let me just again inform the hon. member that this fund is set aside and is run by an administrator. The administrator is dealing with thousands of claims. In fact some 1,700 victims have already been identified and verified by the administrator and are in the process of receiving compensation.
Health April 26th, 2002
Mr. Speaker, the hon. member has to understand that there is not $900 million remaining. In fact the government has committed approximately $1.4 billion. The money that has been set aside under court accepted agreement is to compensate hep C victims over the next 10 to 15 years.
We know full well that individuals may be identified in the years to come. There is a progression in some cases in relation to this illness tragically--
Health April 26th, 2002
Mr. Speaker, the government has been absolutely clear in relation to the approach it has taken to the compensation of certain victims suffering from hepatitis C. In fact a settlement agreement has been entered into. That settlement agreement has been accepted by the court in relation to the action.
The hon. member needs to be aware that the government more than lived up to its obligations in relation to hep C victims.
Reproductive Technologies April 25th, 2002
Mr. Speaker, as I have indicated on a number of occasions in the House, the government will be responding to the report of the Standing Committee on Health as it relates to assisted human reproduction.
As I have indicated in the House many times, we will both be responding to the report and introducing legislation on or before May 10.
Health Care April 25th, 2002
Mr. Speaker, the hon. member is probably aware that as part of the September 2000 accord on health care the first ministers spoke to the challenge of increased drug costs. In light of that accord, federal, provincial and territorial ministers are working together. We are working on a common review process. We are looking at both cost effectiveness issues and utilization issues in relation to prescription drugs.
The hon. member raises a very serious concern, but it is one to which there are not any easy solutions and we will only be able to find a solution if health care professionals and federal, provincial and territorial ministers work together.
Canadian International Trade Tribunal Act April 24th, 2002
moved that the bill be read the third time and passed.
Canadian International Trade Tribunal Act April 24th, 2002
moved that the bill be concurred in.
(Motion agreed to)